Structure Therapeutics is trading 4.06% down at $30.00 on October 1, 2026, amid broad market pressure; no clear company-specific catalyst was identified. - Major U.S. indexes were lower as Treasury yields rose sharply, weighing on equities. - Available coverage described a biotech-sector risk-off backdrop but did not establish it as a direct catalyst. - The company’s investor-relations releases showed no October 1 announcement.